Oxymatrine inhibits renal fibrosis of obstructive nephropathy by downregulating the TGF-β1-Smad3 pathway

References

• Anothaisintawee T, Rattanasiri S, Ingsathit A, Attia J, Thakkinstian A. Prevalence of chronic kidney disease: A systematic review and meta-analysis. Clin Nephrol. 2009;71:244–254.
   PubMed Web of Science ®Google Scholar
• Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383:1831–1843.
   PubMed Web of Science ®Google Scholar
• Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl. 2014;4:2–8.
   Web of Science ®Google Scholar
• Honda E, Park AM, Yoshida K, Tabuchi M, Munakata H. Myofibroblasts: Biochemical and proteomic approaches to fibrosis. Tohoku J Exp Med. 2013;230:67–73.
   PubMed Web of Science ®Google Scholar
• Crisman JM, Richards LL, Valach DP, Franzoni DF, Diamond JR. Chemokine expression in the obstructed kidney. Exp Nephrol. 2001;9:241–248.
   PubMedGoogle Scholar
• Meng XM, Tang PM, Li J, Lan HY. TGF-β/Smad signaling in renal fibrosis. Front Physiol. 2015;6:82.
   PubMed Web of Science ®Google Scholar
• Meng XM, Huang XR, Chung AC, et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol. 2010;21:1477–1487.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bi T, Dai W, et al. Effects of oxymatrine on the proliferation and apoptosis of human hepatoma carcinoma cells. Technol Cancer Res Treat. 2015.
   Web of Science ®Google Scholar
• Zhang Y, Yan R, Hu Y. Oxymatrine inhibits lipopolysaccharide-induced inflammation by down-regulating toll-like receptor 4/nuclear factor-kappa B in macrophages. Can J Physiol Pharmacol. 2015;93:253–260.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang J, Liu YK, et al. Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats. Eur J Pharmacol. 2014;745:29–35.
   PubMed Web of Science ®Google Scholar
• Yang J, Hou Y, Ji G, et al. Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats. Eur J Pharm Sci. 2014;52:180–190.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wu J, Wang H, et al. Liposomal oxymatrine in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment. AAPS PharmSciTech 2014;15:620–629.
   PubMed Web of Science ®Google Scholar
• Shen XC, Yang YP, Xiao TT, Peng J, Liu XD. Protective effect of oxymatrine on myocardial fibrosis induced by acute myocardial infarction in rats involved in TGF-beta(1)-Smads signal pathway. J Asian Natl Prod Res. 2011;13:215–224.
   PubMed Web of Science ®Google Scholar
• Jiang G, Liu X, Wang M, Chen H, Chen Z, Qiu T. Oxymatrine ameliorates renal ischemia-reperfusion injury from oxidative stress through Nrf2/HO-1 pathway. Acta Cir Bras. 2015;30:422–429.
   PubMed Web of Science ®Google Scholar
• Eddy AA, Lopez-Guisa JM, Okamura DM, Yamaguchi I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol. 2012;27:1233–1247.
   PubMed Web of Science ®Google Scholar
• Gustafsson OJ, Briggs MT, Condina MR, et al. MALDI imaging mass spectrometry of N-linked glycans on formalin-fixed paraffin-embedded murine kidney. Anal Bioanal Chem. 2015;407:2127–2139.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim SI, Choi ME. Therapeutic targets for treating fibrotic kidney diseases. Transll Res. 2015;165:512–530.
   PubMed Web of Science ®Google Scholar
• Borges FT, Melo SA, Ozdemir BC, et al. TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol. 2013;24:385–392.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol. 2002;13:96–107.
   PubMed Web of Science ®Google Scholar
• Xavier S, Vasko R, Matsumoto K, et al. Curtailing endothelial TGF-β signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J Am Soc Nephrol. 2015;26:817–829.
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int. 1998;54:1390–1391.
   PubMed Web of Science ®Google Scholar
• Loeffler I, Wolf G. Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transplant. 2014;29:i37–i45.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Mao H, Li S, et al. HSP72 inhibits Smad3 activation and nuclear translocation in renal epithelial-to-mesenchymal transition. J Am Soc Nephrol. 2010;21:598–609.
   PubMed Web of Science ®Google Scholar
• Poosti F, Bansal R, Yazdani S, et al. Selective delivery of IFN-gamma to renal interstitial myofibroblasts: A novel strategy for the treatment of renal fibrosis. FASEB J. 2015;29:1029–1042.
   PubMed Web of Science ®Google Scholar
• Liu L, Lu W, Ma Z, Li Z. Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-beta/Smad signaling pathway. Int J Mol Med. 2012;29:815–822.
   PubMed Web of Science ®Google Scholar
• Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl. 2010;S22–S26.
   Google Scholar
• Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J Am Socf Nephrol. 2000;11:152–176.
   PubMed Web of Science ®Google Scholar
• Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol. 2005;79:5353–5362.
   PubMed Web of Science ®Google Scholar
• Esteban V, Lorenzo O, Ruperez M, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol. 2004;15:1514–1529.
   PubMed Web of Science ®Google Scholar
• Bauge C, Beauchef G, Leclercq S, et al. NFkappaB mediates IL-1beta-induced down-regulation of TbetaRII through the modulation of Sp3 expression. J Cell Mol Med. 2008;12:1754–1766.
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhu S, Chang S, et al. Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: Role of NF-kappa B signaling. Eur J Pharmacol. 2013;720:147--157.
   PubMed Web of Science ®Google Scholar